Noah Berkowitz

Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study

Jacqueline A. French, John A. Lawson, Hiroko Ikeda et al. · The Lancet · 2016 · 747 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study

David Neal Franz, Steven Sparagana, E. Martina Bebin et al. · PLoS ONE · 2016 · 211 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study

David Neal Franz, Steven Sparagana, E. Martina Bebin et al. · The Lancet Oncology · 2014 · 180 citations

Medicine, Neurology, Oncology +9

Everolimus for subependymal giant cell astrocytoma: 5‐year final analysis

David Neal Franz, Karen Agricola, Maxwell Mays et al. · Annals of Neurology · 2015 · 174 citations · Full text

Medicine, Neurology, Pharmacotherapy +13

Everolimus long-term use in patients with tuberous sclerosis complex: Four-year update of the EXIST-2 study

John J. Bissler, J.C. Kingswood, Elżbieta Radzikowska et al. · PLoS ONE · 2017 · 167 citations · Full text

Medicine, Nephrology, Pharmacotherapy +12